JP6712262B2 - 免疫療法に使用するための細胞集団 - Google Patents
免疫療法に使用するための細胞集団 Download PDFInfo
- Publication number
- JP6712262B2 JP6712262B2 JP2017513551A JP2017513551A JP6712262B2 JP 6712262 B2 JP6712262 B2 JP 6712262B2 JP 2017513551 A JP2017513551 A JP 2017513551A JP 2017513551 A JP2017513551 A JP 2017513551A JP 6712262 B2 JP6712262 B2 JP 6712262B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- bdca1
- cd1c
- cell
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A61K40/4273—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14184334.2 | 2014-09-10 | ||
| EP14184333.4 | 2014-09-10 | ||
| EP14184334 | 2014-09-10 | ||
| EP14184333 | 2014-09-10 | ||
| EP14184687 | 2014-09-12 | ||
| EP14184687.3 | 2014-09-12 | ||
| PCT/EP2015/070778 WO2016038168A1 (en) | 2014-09-10 | 2015-09-10 | A cell population for use in treting cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017528470A JP2017528470A (ja) | 2017-09-28 |
| JP2017528470A5 JP2017528470A5 (cg-RX-API-DMAC7.html) | 2019-10-24 |
| JP6712262B2 true JP6712262B2 (ja) | 2020-06-17 |
Family
ID=54196941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513551A Active JP6712262B2 (ja) | 2014-09-10 | 2015-09-10 | 免疫療法に使用するための細胞集団 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10925944B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3191109B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6712262B2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2946697T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016038168A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017136633A1 (en) * | 2016-02-04 | 2017-08-10 | Duke University | Cell-based vaccine compositions and methods of use |
| US11083751B2 (en) | 2016-02-26 | 2021-08-10 | Vib Vzw | Tumor-associated dendritic cell preparations and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2021006316A1 (ja) * | 2019-07-10 | 2021-01-14 | 国立研究開発法人国立がん研究センター | がん細胞を特異的に攻撃しているt細胞を同定するための特異的マーカー |
| WO2021046243A2 (en) | 2019-09-03 | 2021-03-11 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| WO2022241029A1 (en) | 2021-05-11 | 2022-11-17 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| CN120177299B (zh) * | 2024-12-03 | 2026-06-12 | 江苏省人民医院(南京医科大学第一附属医院) | 利用流式细胞仪识别慢性粒单核细胞免疫分型的抗体组合物及方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849589A (en) * | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| AU7499498A (en) * | 1997-05-21 | 1998-12-11 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods and compositions for making dendritic cells from expanded populations ofmonocytes and for activating t cells |
| CA2385792A1 (en) | 1999-10-08 | 2001-04-19 | Dendreon Corporation | Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells |
| JP5007007B2 (ja) | 1999-11-15 | 2012-08-22 | ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 樹状細胞に特異的な抗原結合フラグメント、その組成物および使用方法、それによって認識される抗原およびそれによって得られる細胞 |
| US7030228B1 (en) * | 1999-11-15 | 2006-04-18 | Miltenyi Biotec Gmbh | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| AU3279301A (en) * | 2000-01-11 | 2001-07-24 | Maxygen, Inc. | Monocyte-derived dendritic cell subsets |
| EP1638993A4 (en) * | 2003-06-10 | 2007-05-09 | Univ Melbourne | IMMUNOMODULATING COMPOSITIONS, APPLICATIONS THEREOF AND METHOD FOR THE PRODUCTION THEREOF |
-
2015
- 2015-09-10 WO PCT/EP2015/070778 patent/WO2016038168A1/en not_active Ceased
- 2015-09-10 JP JP2017513551A patent/JP6712262B2/ja active Active
- 2015-09-10 US US15/510,222 patent/US10925944B2/en active Active
- 2015-09-10 ES ES15770464T patent/ES2946697T3/es active Active
- 2015-09-10 EP EP15770464.4A patent/EP3191109B1/en active Active
-
2020
- 2020-07-22 US US16/936,396 patent/US11612644B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10925944B2 (en) | 2021-02-23 |
| EP3191109A1 (en) | 2017-07-19 |
| US11612644B2 (en) | 2023-03-28 |
| WO2016038168A1 (en) | 2016-03-17 |
| JP2017528470A (ja) | 2017-09-28 |
| EP3191109B1 (en) | 2023-03-29 |
| US20170258882A1 (en) | 2017-09-14 |
| ES2946697T3 (es) | 2023-07-24 |
| US20210038702A1 (en) | 2021-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lamb et al. | Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future | |
| US11612644B2 (en) | Cell population for use in treating cancer | |
| Perri et al. | Immune response against head and neck cancer: biological mechanisms and implication on therapy | |
| Lecciso et al. | ATP release from chemotherapy-treated dying leukemia cells elicits an immune suppressive effect by increasing regulatory T cells and tolerogenic dendritic cells | |
| Martins et al. | Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker | |
| US20210292433A1 (en) | Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination | |
| CA2413866C (en) | Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations | |
| KR20260040322A (ko) | 키메라 항원 수용체 t세포 요법 | |
| JP2018531274A (ja) | 炎症促進性細胞へのマクロファージ分極を改変して癌を治療するための方法及び組成物 | |
| Hong et al. | Human acute myeloid leukemia blast-derived exosomes in patient-derived xenograft mice mediate immune suppression | |
| US20190225941A1 (en) | Modulation of function of immune effector cells | |
| WO2020180733A1 (en) | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof | |
| JP2017535543A (ja) | 腫瘍内微小環境に影響を与えるベータ−グルカン方法と組成物 | |
| JP2022512161A (ja) | 免疫療法のための組成物及び方法 | |
| WO2022265864A2 (en) | Tim-3 modulates anti-tumor immunity by regulating inflammasome activation | |
| KR20170141713A (ko) | Ctla-4 길항제를 사용하여 면역 반응을 증강시키는 방법 | |
| Takeda et al. | Type I interferon-independent dendritic cell priming and antitumor T cell activation induced by a Mycoplasma fermentans lipopeptide | |
| JP2022543026A (ja) | Nk細胞を評価するためのシステム及び方法 | |
| KR20250097844A (ko) | 면역요법의 효능 향상 및 지속적인 반응 | |
| Semiannikova | Investigating determinants of sensitivity and resistance to T cell redirecting antibodies in colorectal cancer through patient derived organoid models | |
| US20250367289A1 (en) | Dosage regimen for a combination therapy consisting oftcr-engineered t-cells in combination with a pd-1 axis binding antagonist | |
| WO2024098024A1 (en) | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof | |
| WO2025096517A1 (en) | Factors for optimizing immunotherapy efficacy | |
| Funck | Innate immune cell crosstalk induces melanoma cell senescence | |
| Kline | The Innate Immune System Drives T Cell Tolerance Against Acute Myeloid Leukemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170510 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180816 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190619 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190911 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20190911 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20191204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200327 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200330 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20200416 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200520 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200529 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6712262 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |